(R)-6-(Amino(4-Chlorophenyl)(1-Methyl-1H-Imidazol-5-Yl)Methyl)-4-(3-Chlorophenyl)-1-Methylquinolin-2(1H)-One (R)-6-(氨基(4-氯苯基)(1-甲基-1H-咪唑-5-基)甲基)-4-(3-氯苯基)-1-甲基-2(1H)-喹啉酮
CAS 192185-72-1 MFCD07772347
化学结构图
SMILES: Cn1cncc1C(N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C
化学属性
| Mol. Formula | C27H22Cl2N4O |
|---|---|
| Mol. Weight | 489.4 |
别名和识别编码
| Chemical Name | (R)-6-(Amino(4-Chlorophenyl)(1-Methyl-1H-Imidazol-5-Yl)Methyl)-4-(3-Chlorophenyl)-1-Methylquinolin-2(1H)-One |
|---|---|
| CAS Number | 192185-72-1 |
| Synonym | (R)-(+)-R 115777 (R)-6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 2 (1H))-quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-,(+)- 6-[(R)-Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone R 115777 R-115777 R115777 Zarnestra tipifarnib |
| Chemical Name Translation | (R)-6-(氨基(4-氯苯基)(1-甲基-1H-咪唑-5-基)甲基)-4-(3-氯苯基)-1-甲基-2(1H)-喹啉酮 |
| PubChem Substance ID | 159324 |
| InChI | InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1 |
| LabNetwork Molecule ID | LN01301159 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- Amines
- Aromatics
- Heterocycles
- Pharmaceuticals
- Intermediates & Fine Chemicals
- Tyrosine Kinase Inhibitors
产品应用
- ########
相关文献及参考
- [2]. Martin LA, et al. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with ICI 47699 acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol Cancer Ther. 2007 Sep;6(9):2
- [3]. End DW, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001 Jan 1;61(1):131-7
- [4]. Amrita Datta, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep. 2018 May 25;8(1):8161.
- David, E., et al.: Blood, 116, 5285 (2010); Nagai, T., et al.: Leukemia Res., 34, 1057 (2010); Hong, D., et al.: Clin. Cancer Res., 15, 7061 (2009)
- [1]. Devendra S Puntambekar, et al. Inhibition of farnesyltransferase: a rational approach to treat cancer? J Enzyme Inhib Med Chem. 2007 Apr;22(2):127-40.
